IMPORTANT MESSAGE
Like many other companies and institutions around the world, we are experiencing interference with some of our systems within the TNT network.
We are implementing remediation steps as quickly as possible. We have implemented operational contingencies to continue to complete collections from customers with scheduled stops. For customers who do not have a regular stop, collection should be arranged via our customer service centers.
Customers may experience delays in the transit of shipments, particularly inter-continental or non-EU European delivery, as we work to remediate our systems. Additionally, if customers do not have the facility for self-labeling, they may also experience delays.
We are not able to collect shipments of dangerous goods at this time.
We regret any inconvenience to our customers.
Clinical Supply Chain Management – Large Biotech – Phase III Study
Clinical Supply Chain Management – Large Biotech – Phase III Study
Large Biotech Saves $1.8 Million on Phase III Study
Our client, a large biotech company, was planning a multinational, phase III trial involving 800 patients to compare the efficacy, safety and tolerability of the IMP with a comparator drug product for the treatment of Multiple Sclerosis.
To eliminate bias, the study was designed to be a randomised, double-blinded, placebo-controlled, parallel group equivalence trial, conducted in 17 countries involving 140 sites located in Western Europe, Russia, Ukraine, United States, Latin America and South Africa. Study participants were randomly assigned to receive IMP, comparator or a placebo for 9 months, followed by open label treatment for 15 months. The sponsor company approached Almac to provide the following services throughout the duration of the study:
- Forecasting and Supply Chain Management Services
- Development of Master English Text
- Comparator Procurement
- Packaging, Distribution and Depot Service
